This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Jul 2011

Alkermes Reports ALKS 33 Phase II Results

The results were not significantly different from that observed with placebo, and hence Alkermes has determined not to pursue further development of ALKS 33 in this treatment area.

Alkermes has released the results of a Phase II trial designed to assess the safety and efficacy of daily oral administration of ALKS 33 in patients with binge eating disorder.

 

The results were not significantly different from that observed with placebo, and hence Alkermes has determined not to pursue further development of ALKS 33 in this treatment area.

 

The randomised, double-blind and placebo-controlled study involved 68 patients. It demonstrated that ALKS 33 reduced the efficacy endpoint of self-reported weekly binge eating episodes from baseline.

 

ALKS 33 is currently being evaluated as a treatment for alcohol dependence and, in combination with buprenorphine as ALKS 5461, for cocaine addic

Related News